EcoDrugPlus

Protein Phosphatase 3 Catalytic Subunit Alpha

Ensembl ID : ENSAPEG00000021489
Gene Symbol: PPP3CA
2 Cross references
233 Possible Orthologues:

Protein Tyrosine Kinase 2

Ensembl ID : ENSAPEG00000005023
Gene Symbol: PTK2
1 Cross references
241 Possible Orthologues:

Protein Tyrosine Kinase 2 Beta, B

Ensembl ID : ENSAPEG00000001933
Gene Symbol: PTK2BB
1 Cross references
196 Possible Orthologues:

Protein Tyrosine Phosphatase Non-Receptor Type 11a

Ensembl ID : ENSAPEG00000010912
Gene Symbol: PTPN11A
1 Cross references
253 Possible Orthologues:

Protein Tyrosine Phosphatase Receptor Type B

Ensembl ID : ENSAPEG00000024112
Gene Symbol: PTPRB
2 Cross references
193 Possible Orthologues:

Purinergic Receptor P2x, Ligand-Gated Ion Channel, 3a

Ensembl ID : ENSAPEG00000011812
Gene Symbol: P2RX3A
1 Cross references
194 Possible Orthologues:

Purinergic Receptor P2x, Ligand-Gated Ion Channel, 3b

Ensembl ID : ENSAPEG00000020485
Gene Symbol: P2RX3B
1 Cross references
200 Possible Orthologues:

Purinergic Receptor P2x, Ligand-Gated Ion Channel, 7

Ensembl ID : ENSAPEG00000020631
Gene Symbol: P2RX7
1 Cross references
195 Possible Orthologues:

Purinergic Receptor P2y1

Ensembl ID : ENSAPEG00000001362
Gene Symbol: P2RY1
1 Cross references
191 Possible Orthologues:

Purinergic Receptor P2y12

Ensembl ID : ENSAPEG00000001109
Gene Symbol: P2RY12
1 Cross references
182 Possible Orthologues:

Purinergic Receptor P2y2

Ensembl ID : ENSAPEG00000016001
Gene Symbol: P2RY2
1 Cross references
200 Possible Orthologues:

Pyrimidinergic Receptor P2y4

Ensembl ID : ENSAPEG00000007813
Gene Symbol: P2RY4
2 Cross references
168 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).